Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

BACKGROUND: In 2013, an estimated 686,000 people died from hepatitis B virus (HBV) infection worldwide. Mass treatment programmes for hepatitis B will require very low drug costs. International treatment guidelines recommend first-line monotherapy with either entecavir or tenofovir disoproxil fumara...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew, Gotham, Dzintars, Cooke, Graham, Bhagani, Sanjay, Andrieux-Meyer, Isabelle, Cohn, Jennifer, Fortunak, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946675/
https://www.ncbi.nlm.nih.gov/pubmed/27482399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946675/
https://www.ncbi.nlm.nih.gov/pubmed/27482399

Ejemplares similares